Evidence-based workflow integrating updated KDIGO supportive care, Oxford MEST-C risk stratification, and emerging targeted therapies (Nefecon, sparsentan, atrasentan, sibeprenlimab, iptacopan) to slow progression and preserve nephron function.
Developed by Craig G. Hurwitz, MD
[One sentence guiding the clinician on what they're choosing.]
[Primary reference — author list. Title in italics. Journal year;volume(issue):pages. doi:...]
[Secondary reference — e.g. relevant society guideline.]
